Refinement of screening for familial pancreatic cancer

Author(s):
Bartsch, D.K.; Slater, E.P.; Carrato, A.; Ibrahim, I.S.; Guillen-Ponce, C.; Vasen, H.F.A.; Matthai, E.; Earl, J.; Jendryschek, F.S.; Figiel, J.; Steinkamp, M.; Ramaswamy, A.; Vazquez-Sequeiros, E.; Munoz-Beltran, M.; Montans, J.; Mocci, E.; Bonsing, B.A.; Wasser, M.; Kloppel, G.; Langer, P.; Fendrich, V.; Gress, T.M.
Published
2016
Publication type
Article / Letter to editor

Abstract

Conclusions It appears safe to start screening for PDAC in IAR of non-CDKN2a FPC families at the age of 50 years. MRI-based screening supplemented by EUS at baseline and every 3rd year or when changes in MRI occur appears to be efficient.

Date issued
2016-08-01
Language
English
Publisher
BMJ PUBLISHING GROUP
Is part of
Gut (2016), Vol. 65, no. 8, p. 1314-1321
hdl
1887/117213
doi
10.1136/gutjnl-2015-311098